Qube Research & Technologies (QRT)’s CRISPR Therapeutics CRSP Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-17,188	Closed	-$928K	–	3443
2024 Q2	$928K	Buy	17,188 +4,746	+38%	+$275K	﹤0.01%	1927
2024 Q1	$848K	Buy	+12,442	New	+$891K	﹤0.01%	2242
2023 Q4	–	Sell	-3,698	Closed	-$168K	–	4399
2023 Q3	$168K	Sell	3,698 -808	-18%	-$41.7K	﹤0.01%	2460
2023 Q2	$253K	Buy	+4,506	New	+$256K	﹤0.01%	1710
2023 Q1	–	Sell	-15,594	Closed	-$634K	–	2605
2022 Q4	$634K	Buy	+15,594	New	+$827K	﹤0.01%	1389
2022 Q2	–	Sell	-81,592	Closed	-$5.12M	–	2590
2022 Q1	$5.12M	Buy	81,592 +53,414	+190%	+$3.35M	0.04%	519
2021 Q4	$2.13M	Buy	+28,178	New	+$2.46M	0.02%	823
2021 Q3	–	Sell	-11,327	Closed	-$1.83M	–	2298
2021 Q2	$1.83M	Buy	+11,327	New	+$1.38M	0.02%	731
2021 Q1	–	Sell	-14,344	Closed	-$2.2M	–	1986
2020 Q4	$2.2M	Sell	14,344 -3,111	-18%	-$368K	0.03%	583
2020 Q3	$1.46M	Buy	+17,455	New	+$1.55M	0.02%	716
2020 Q1	–	Sell	-13,348	Closed	-$813K	–	1213
2019 Q4	$813K	Buy	+13,348	New	+$729K	0.03%	704

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CRSP Position: Q3 2024 in Review

Qube Research & Technologies (QRT) sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 17,188 shares — an estimated $928K sold.

Qube Research & Technologies (QRT) first reported a position in CRSP in Q4 2019 and held it in 11 quarters. The position peaked at $5.12M in Q1 2022. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

Qube Research & Technologies (QRT) reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 17,188 CRISPR Therapeutics shares in Q3 2024, an estimated $928K.
Qube Research & Technologies (QRT) first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 11 quarters.
Qube Research & Technologies (QRT)'s CRISPR Therapeutics position peaked at $5.12M in Q1 2022.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q3 2024, filed 14 Nov 2024.